Novo Nordisk Eyes Turnaround as Oral Wegovy Challenges Eli Lilly in Weight-Loss Drug Race 
Meta Cuts Wipro Outsourcing by 25% After AI-Led Restructuring 
Vast Eyes Hong Kong IPO as Chinese AI Unicorn Gains Momentum 
Boeing Stock Jumps as FAA Certifies 737 MAX-7 After Years of Regulatory Review 
Trump Urges Exxon, Chevron to Cut Gas Prices After Record Oil Profits 
HSBC H1 Profit Jumps 23%, Announces $1 Billion Share Buyback and Reaffirms 2028 Targets 
Bayer Q2 Earnings Beat Forecasts as Crop Science Boosts Results, Debt Outlook Improves 
BYD July Global Vehicle Sales Rise 22% as Overseas Demand Surges 
Samsung, SK Hynix Test AMEC Chipmaking Tools for China Backup Plan 
Warner Bros. Discovery Shares Rise as Newsom Pushes Settlement in $110 Billion Merger Fight 
Colgate-Palmolive Reaffirms 2026 Sales Outlook Despite Weak North America Demand 
T-Mobile Executives Reportedly Oppose $300 Billion Deutsche Telekom Merger 
Apple Restores Telegram to App Store After Content Policy Violation 
Prysmian Nears Deal to Acquire Atkore in Potential All-Cash Takeover 
AstraZeneca, Bristol Myers Squibb Explore Mega Merger Worth Nearly $400 Billion 
Capital One Says AML Review Led to Closure of Trump Organization Accounts 
SK Hynix Bonus Dispute Deepens as Union Rejects Stock-Based Payout Proposal 
DURHAM, N.C., April 02, 2018 -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company developing novel antivirals for the growing population of immunocompromised patients, today announced that Garrett Nichols, M.D., M.S., Chief Medical Officer of Chimerix will present at the H.C. Wainwright Annual Global Life Sciences Conference on Monday, April 9, 2018 at 10:15 a.m. CET at the Le Meridien Beach Plaza Hotel in Monte Carlo, Monaco.
A live audio webcast of the presentation will be available on the Investor Relations section of Chimerix’s website at ir.chimerix.com, where it will be archived for approximately 90 days.
About Chimerix
Chimerix is a biopharmaceutical company dedicated to discovering, developing and commercializing medicines that improve outcomes for immunocompromised patients. Chimerix's proprietary lipid conjugate technology and compound library have produced brincidofovir (BCV, CMX001); CMX157, which was licensed to ContraVir Pharmaceuticals; and a new clinical candidate, CMX521, the first direct-acting antiviral specifically for the treatment and prevention of norovirus. For further information, please visit Chimerix's website, www.chimerix.com.
CONTACT:
Investor Relations:
Michelle LaSpaluto
(919) 972-7115
[email protected]
or
Will O’Connor
Stern Investor Relations
[email protected]
212-362-1200
Media:
Becky Vonsiatsky
W2O Group
[email protected]
413-478-2003
